Milestone Pharmaceuticals (NASDAQ:MIST) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a hold rating to a sell rating in a research note published on Saturday morning.

MIST has been the topic of a number of other research reports. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 15th. Raymond James Financial assumed coverage on shares of Milestone Pharmaceuticals in a research note on Friday. They set a “strong-buy” rating and a $6.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Milestone Pharmaceuticals in a research note on Tuesday, January 6th. Finally, Wells Fargo & Company raised their target price on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Milestone Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $7.50.

Milestone Pharmaceuticals Price Performance

Shares of NASDAQ:MIST opened at $2.00 on Friday. The firm’s 50 day moving average price is $1.63 and its 200-day moving average price is $1.94. Milestone Pharmaceuticals has a twelve month low of $0.77 and a twelve month high of $3.06. The company has a quick ratio of 7.96, a current ratio of 8.01 and a debt-to-equity ratio of 1.37. The stock has a market capitalization of $235.34 million, a PE ratio of -2.53 and a beta of 0.69.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings data on Friday, March 20th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02. The business had revenue of $1.44 million during the quarter, compared to the consensus estimate of $37.52 million. Equities research analysts expect that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

Insider Activity

In other news, CEO Joseph Oliveto sold 34,523 shares of Milestone Pharmaceuticals stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $1.93, for a total transaction of $66,629.39. Following the sale, the chief executive officer owned 482,744 shares in the company, valued at $931,695.92. This trade represents a 6.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 70,193 shares of company stock worth $135,472 in the last quarter. Company insiders own 19.50% of the company’s stock.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of MIST. Creative Planning raised its position in shares of Milestone Pharmaceuticals by 74.6% during the second quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after buying an additional 10,000 shares during the last quarter. Raymond James Financial Inc. raised its position in shares of Milestone Pharmaceuticals by 30.1% during the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock valued at $84,000 after buying an additional 10,000 shares during the last quarter. Valeo Financial Advisors LLC raised its position in shares of Milestone Pharmaceuticals by 553.5% during the second quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company’s stock valued at $254,000 after buying an additional 110,699 shares during the last quarter. Sapient Capital LLC bought a new stake in shares of Milestone Pharmaceuticals during the third quarter valued at approximately $25,000. Finally, Simplify Asset Management Inc. raised its position in shares of Milestone Pharmaceuticals by 186.2% during the third quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock valued at $5,666,000 after buying an additional 1,842,974 shares during the last quarter. Institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.